Status:
RECRUITING
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Lead Sponsor:
ImmVira Pharma Co. Ltd
Conditions:
Solid Tumor
Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced o...
Detailed Description
This is a Phase 1/2a, open-label, first-in-human study of T3011 given via intratumoral (IT) injection as a single agent and in combination with IV pembrolizumab in participants with advanced or metast...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
September 17 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 10 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04370587
Start Date
September 17 2020
End Date
January 10 2027
Last Update
October 8 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States, 85234
2
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
3
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
4
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15232